Harrow, Inc. Deferred Offering Costs
Harrow, Inc. (HROW) had Deferred Offering Costs of $14.42 million as of 2014-03-31, per its 10-Q filed 2014-05-15.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2014-05-15
- 2014-03-31: Deferred Offering Costs $14.42M.
- 2013-12-31: Deferred Offering Costs $15.73M.
- 2013-03-31: Deferred Offering Costs $0.00.
- 2012-12-31: Deferred Offering Costs $596.28K.
| Period end | Deferred Offering Costs |
|---|---|
| 2014-03-31 | $14.42M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $15.73M 10-Q · filed 2014-05-15 |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-08 |
| 2012-12-31 | $596.28K 10-K · filed 2014-03-28 |
| 2012-09-30 | $383.75K 10-Q · filed 2012-11-14 |
| 2012-06-30 | $117.73K 10-Q · filed 2012-08-14 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |